Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor.

Subjects who were taking gabapentinoids also showed a trend toward pain reduction, although not statistically significant, and the difference in pain score between placebo and VM202 groups was much smaller than for nonusers.

also in 53,322 other papers